
News|Articles|November 29, 2012
Study: Similar safety, efficacy with dabigatran versus warfarin in diabetic patients with Afib
Patients with nonvalvular atrial fibrillation (NVAF) who also have diabetes experienced similar safety and efficacy with dabigatran etexilate mesylate (Pradaxa) 150 mg or dabigatran 110 mg relative to warfarin, in comparison to patients without diabetes who have NVAF, according to data presented at American Heart Association's Scientific Sessions 2012.
Advertisement
Newsletter
Get the latest industry news, event updates, and more from Managed healthcare Executive.
Advertisement
Advertisement
Advertisement
Trending on Managed Healthcare Executive
1
Jascayd gets second FDA approval, this time for progressive pulmonary fibrosis
2
2025 FDA added indications to dermatologic medications
3
What NCCN’s next CMO sees ahead for cancer guidelines, access and innovation
4
5 developments in the treatment of prurgio nodularis in 2025
5




















































